http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2504385-C2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_274e6453924e1e4ceb84fe951b212ce9
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M1-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-067
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
filingDate 2010-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2014-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ce76985351bfb113adac0651467b3a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db918831c4e3ff0a6fd11e0e780e5fec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91351cde657d29aad9e8d1df1900542a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1200c7faed4197e3a7c1f3e31e3a6f79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9be0aedb4408ecab001318120a54c499
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_063acfedf4efc5abd91491de408c5b87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f988e7f2a4d1d871f732d0cd2372777
publicationDate 2014-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2504385-C2
titleOfInvention Method of treating patients with complicated forms of diabetic foot
abstract FIELD: medicine. n SUBSTANCE: invention refers to medicine. A method of treating the patients with the complicated forms of diabetic foot by blood sampling, centrifugation, plasma removal, erythrocyte fraction recovery, introduction of the angiotropic drug alprostadil, exposure to laser light at power 12 mWt for 20 minutes, addition of normal saline 100 ml in erythrocyte fraction 200 ml and reinfusion for 1.5-2 hours; ATP 2 ml is combined with the angiotropic drug alprostadil and introduced into the erythrocyte fraction; the erythrocyte fraction is reinfused every second day, alternated with intravenous drop-by-drop introduction of Vessel-DUE-F 600 LSU and actovegin 5 ml per normal saline 100 ml; the therapeutic course is 10 days. n EFFECT: using the method provides higher effectiveness and reduces the length of treatment of the patients with the complicated forms of diabetic foot syndrome, promotes the longer preservation of the achieved therapeutic effect.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2704977-C1
priorityDate 2010-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2363499-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2367446-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2243767-C1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID632
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID632
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590105
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280723
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448670727
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234

Total number of triples: 33.